The European Medicines Agency has Launched a New Web Site
The European Medicines Agency has launched a new, user-focused, interactive website today. The website - which continues on the same address http://www.ema.europa.eu - has been redesigned in direct response to the Agency's research into the types of features and functionality our users would like to see.
New features include:
* Quick medicine searches: Allows you to search for human and veterinary medicines by name and active substance and for herbal medicinal substances by name
* An online library: Enables you to search for all Agency documents currently online through a search on title and date published online.
* Improved navigation: More intuitive labelling and improved organisation of content so that browsing is quicker for all audience groups.
* Audience landing pages: Flags information of specific value to different key users.
* Online calendar and news search: Allows you to keep up to date with the latest news and events at the Agency.
* RSS feeds: Brings information straight to you as soon as it is published online.
Using Patient Reported Outcomes in Dermatology Trials
April 25th 2024In part 3 of this video interview with ACT editor Andy Studna, Melissa Mooney, director, eCOA sales engineering, IQVIA sheds light on the unique challenges of dermatology trials and how clinical outcome assessments can be implemented in them.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Grants Ziftomenib with Breakthrough Therapy Designation for NPM1-Mutant Acute Myeloid Leukemia
April 23rd 2024Data from the Phase Ib portion of the KOMET-001 trial showed that the once-daily oral treatment may provide a substantial improvement over available therapies for relapsed/refractory NPM1-mutant acute myeloid leukemia.
